atazanavir sulfate has been researched along with ritonavir in 471 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 150 (31.85) | 29.6817 |
| 2010's | 286 (60.72) | 24.3611 |
| 2020's | 35 (7.43) | 2.80 |
| Authors | Studies |
|---|---|
| Haas, DW; Jaeger, H; Nunes, D; Piliero, P; Schnittman, S; Schrader, S; Sension, M; Thiry, A; Zala, C | 1 |
| Sax, PE | 2 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Piketty, C; Taburet, AM; Vincent, I | 1 |
| Wehr, A | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Benzie, AA; Boffito, M; Gazzard, BG; Hill, A; Kruse, G; Kurowski, M; Moyle, GJ; Nelson, MR; Pozniak, AL | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 2 |
| Feldt, T; Göbels, K; Häussinger, D; Kroidl, A; Kuschak, D; Leidel, R; Oette, M; Sagir, A | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Clotet, B; Fuster, D | 1 |
| Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM | 1 |
| Bonnard, P; Guiard-Schmid, JB; Jaillon, P; Lukiana, T; Meynard, JL; Pialoux, G; Poirier, JM; Slama, L | 1 |
| Adler, E; Cohen, C; Fessel, WJ; Gladysz, A; Gonzalez-Garcia, J; McGovern, R; McLaren, C; Nieto-Cisneros, L; Zala, C | 1 |
| Hill, A | 1 |
| Hruz, PW; Yan, Q | 1 |
| Calvez, V; Flandre, P; Günthard, HF; Hirsch, HH; Marcelin, AG; Masquelier, B; Perrin, L; Peytavin, G; Vora, S; Yerly, S; Zinkernagel, A | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Altice, FL; Bruce, RD | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Decosterd, LA; Franc, C; Guignard, N; Khonkarly, M; Rochat, B; Tarr, PE; Telenti, A | 1 |
| Bonnard, P; Guiard-Schmid, JB; Meynard, JL; Poirier, JM | 1 |
| Crum, NF; Furtek, KJ; Olson, PE; Wallace, MR | 1 |
| Naeger, LK; Struble, KA | 1 |
| Chan-Tack, KM; Edozien, A | 1 |
| Crane, HM; Kitahata, MM; Van Rompaey, SE | 1 |
| Bonnard, P; Girard, PM; Guiard-Schmid, JB; Jaillon, P; Lukiana, T; Meynard, JL; Pialoux, G; Poirier, JM; Zouai, O | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Gérard, L; Girard, PM; Marcelin, AG; Piketty, C; Saïdi, Y | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Madelaine-Chambrin, I; Marcelin, AG; Molina, JM; Piketty, C; Taburet, AM | 1 |
| Azuaje, C; Crespo, M; Curran, A; Diaz, M; Feijoo, M; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Boucher, S; Breilh, D; Fleury, H; Lazaro, E; Neau, D; Pellegrin, I; Pellegrin, JL; Ragnaud, JM; Saux, MC; Schrive, MH; Vray, M | 1 |
| Bastow, B; Coombs, RW; DiRienzo, AG; Fletcher, CV; Godfrey, C; Margolis, DM; McKinnon, J; Mellors, JW; Ray, MG; Swindells, S; Thal, GD; Wang, H; Wilkin, T | 1 |
| Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Hill, A; Maitland, D; Moyle, G; Nelson, M; Pozniak, A | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Csajka, C; Décosterd, LA; Telenti, A | 1 |
| Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F | 1 |
| Flint, OP; Maa, JF; Noor, MA; Parker, RA | 1 |
| Back, D; Boffito, M; Ford, J; Gazzard, B; Hill, A; Khoo, S; Maitland, D; Moyle, G; Nelson, M; Pozniak, A | 1 |
| Johnson, M | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Aouadi, M; Binétruy, B; Cardot-Leccia, N; Dellamonica, P; Durant, J; Garraffo, R; Heripret, L; Lavrut, T; Le Marchand-Brustel, Y; Perrin, C; Prot, M | 1 |
| Agarwala, S; Been-Tiktak, A; Bertz, R; Burger, DM; Child, M; Wang, Y | 1 |
| Ballard, C; Best, B; Caperna, J; Capparelli, E; Goicoechea, M; Haubrich, R | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Chan-Tack, KM; Fantry, LE; Gilliam, BL; Qaqish, RB; Redfield, RR; Rode, RA | 1 |
| Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Martín-Carbonero, L; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Josephson, F; Karlström, O; Sönnerborg, A | 1 |
| Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Acosta, EP; Becker, SL; Kakuda, TN; King, JR; Paul, S; Tse, MM | 1 |
| Dauer, B; Harder, S; Klauke, S; Kurowski, M; Lutz, T; Müller, A; Oertel, B; Rottmann, C; Staszewski, S; von Hentig, N; Wolf, T | 1 |
| DiFrancesco, R; Fischl, MA; Gripshover, B; Hochreitter, J; Keil, K; Morse, GD; Reichman, RC; Zingman, BS | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V | 1 |
| Blanco, JL; Gatell, JM; López-Púa, Y; Mallolas, J; Martínez, E; Nomdedeu, M; Sarasa, M; Soriano, A | 1 |
| Agarwala, S; Barditch-Crovo, P; Carson, K; Flexner, C; Fuchs, E; Parsons, T; Pham, PA; Vasist, L | 1 |
| Cooper, DA; Emery, S; Law, M; MacRae, K; Mallon, PW; Satchell, C; Schutz, M; Williams, KM; Winston, A | 1 |
| Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM | 1 |
| Aboulker, JP; Chazallon, C; Gérard, L; Girard, PM; Piketty, C; Taburet, AM | 1 |
| Daneel, S; Decosterd, L; Fierz, W; Hirschel, B; Hoffmann, M; Klimkait, T; Schiffer, V; Vernazza, P | 1 |
| Arduino, RC; Barnett, BJ; Torres, HA | 1 |
| Giratto, JE; Girotto, JE; Salazar, JC; St Germain, RM; Wells, L; Yigit, S | 1 |
| Gianotti, N; Lazzarin, A; Soria, A | 1 |
| DiFrancesco, R; Friedland, G; Ma, Q; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, P; Rainey, PM | 1 |
| Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Bower, M; Gazzard, B; Holmes, P; Jones, R; McKenna, A; Nathan, B; Nelson, M; Powles, T; Stebbing, J | 1 |
| Back, D; Boffito, M; Bonora, S; D'Avolio, A; Else, L; Gazzard, B; Mandalia, S; Moyle, G; Nelson, M; Pozniak, A; Waters, LJ | 1 |
| Caby, F; Daudon, M; Izzedine, H; Katlama, C; Mohand, HA; Valantin, MA | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Blanco, A; Clotet, B; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M | 1 |
| Arribas, JR; Pulido, F | 1 |
| David, N; Hammond, J; Krantz, E; Malan, DR; McGrath, D; Wirtz, V | 1 |
| Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN | 1 |
| Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM | 1 |
| Airoldi, M; Bertuletti, P; Cattaneo, D; Frigerio, L; Maggiolo, F; Ripamonti, D; Ruggeri, M; Suter, F | 1 |
| Castagna, A; Caumo, A; Galli, L; Guffanti, M; Lazzarin, A; Luzi, L; Perseghin, G | 1 |
| Antinori, A; Bertoli, A; Caramello, P; Cargnel, A; Carosi, G; Di Perri, G; Esposito, R; Filice, G; Lazzarin, A; Lorenzini, P; Maserati, R; Moroni, M; Narciso, P; Perno, CF; Rizzardini, G; Santoro, MM | 1 |
| Athichathanabadi, C; Bowonwatanuwong, C; Chaovavanich, A; Chumpathat, N; Manosuthi, W; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S; Tantisiriwat, W | 1 |
| Abdel-Kader, L; Camacho, A; Lozano, F; Macías, J; Palacios, R; Pineda, JA; Rivero, A; Santos, J | 1 |
| Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Herrington, JD; Maclayton, DO; Nguyen, ST; Payne, KD; Rahman, AP; Rodriguez-Barradas, MC | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Bedimo, R; Busti, AJ; Hardin, DS; Margolis, DM | 1 |
| Goshima, C; Jinno, S | 1 |
| Ceccarelli, G; D'Ettorre, G; Massetti, AP; Mastroianni, CM; Vullo, V; Zaffiri, L | 1 |
| Bacarelli, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Navarra, P; Ragazzoni, E; Regazzi, M; Villani, P | 1 |
| von Hentig, N | 1 |
| Babacan, E; Kaykhin, P; Lötsch, J; Staszewski, S; Stephan, C; Stürmer, M; von Hentig, N | 1 |
| Beck, K; Cai, Y; Causemaker, SJ; Chiu, YL; Doan, T; Esslinger, HU; Hanna, GJ; King, KR; Klein, CE; Podsadecki, TJ | 1 |
| Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
| Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A | 1 |
| Babacan, E; Carlebach, A; Haberl, A; Harder, S; Knecht, G; Lennemann, T; Staszewski, S; von Hentig, N | 1 |
| Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Fukushima, K; Haraya, K; Ito, Y; Sugioka, N; Takada, K; Terasaka, S | 1 |
| Bain, AM; Bedimo, RG; Busti, AJ; Hall, RG; Leff, RD; Meek, C; Mehvar, R | 1 |
| Bertz, RJ; Burger, DM; Huisman, A; Koopmans, P; Neisingh, H; Rongen, GA; Van Ewijk, N; Van Uden, P | 1 |
| Gallagher, DP; Kieran, J; Lambert, J; Mahon, N; Mallon, PW; Sheehan, G | 1 |
| Cruttenden, K; DiCenzo, R; Gelbard, H; Hochreiter, J; Mariuz, P; Peterson, DR; Rezk, NL; Schifitto, G | 1 |
| Back, DJ; Jones, SP; Pirmohamed, M; Sutton, R; Waitt, C | 1 |
| Dubé, MP; Greenwald, M; Mather, KJ; Shen, C | 1 |
| Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H | 1 |
| Keiser, PH; Nassar, N | 1 |
| Roca, B | 1 |
| Esteban Mur, JI; Juárez Giménez, JC; López Galera, RM; Montoro Ronsano, JB; Ribera Pascuet, E | 1 |
| Frank, I; Torti, C | 1 |
| Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Thiry, A; Yang, R | 1 |
| Chin, BS; Choi, H; Choi, JY; Choi, SH; Han, SH; Jeong, SJ; Kim, CO; Kim, JM; Kim, MS; Lee, HS; Song, YG | 1 |
| Anunnatsiri, S; Chetchotisakd, P | 1 |
| Bendayan, M; Bendayan, R; Chan, GN; Couraud, PO; Ramaswamy, M; Romero, IA; Ronaldson, PT; Weksler, B; Zastre, JA | 1 |
| Louis, JM; Sayer, JM | 1 |
| Cornely, OA; Fätkenheuer, G; Hartmann, P; Hofmann, A; Jung, N; Lehmann, C; Wyen, C | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Khoo, S; Moyle, G; Pozniak, A; Sousa, M; Taylor, J | 1 |
| Best, BM; Brigid, E; Capparelli, EV; Clifford, DB; Collier, AC; Ellis, R; Gelman, BB; Grant, I; Letendre, SL; McArthur, JC; McCutchan, JA; Simpson, DM | 1 |
| Bierman, WF; Boucher, CA; Danner, SA; Nijhuis, M; van Agtmael, MA | 1 |
| Avihingsanon, A; Burger, DM; Chanmano, S; Cooper, DA; Gorowara, M; Kerr, SJ; Lange, J; Ohata, P; Phanuphak, P; Ruxrungtham, K; van der Lugt, J | 1 |
| Ameli, N; Anastos, K; Bacchetti, P; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Hyman, CL; Levine, A; Young, M | 1 |
| Antinori, A; Barbarini, G; Bertoli, A; Bini, T; Caramello, P; Ceccherini-Silberstein, F; Di Perri, G; Gianotti, N; Lorenzini, P; Maserati, R; Melzi, S; Micheli, V; Mussini, C; Narciso, P; Perno, CF; Santoro, MM; Torti, C | 1 |
| Bastow, B; Coffin, JM; DiRienzo, AG; Fletcher, CV; Godfrey, C; Maldarelli, F; Margolis, DM; McKinnon, JE; Mellors, JW; Mollan, K; Palmer, S; Swindells, S; Thal, G; Wiegand, A; Wilkin, TJ; Woodward, W | 1 |
| Acosta, EP; Alston-Smith, B; Bertz, R; Child, MJ; Gerber, JG; Haas, DW; Hosey, L; Kendall, MA; Koletar, SL; Laughlin, L; Suckow, C; Zolopa, AR | 1 |
| Diego Miralles, G; Lefebvre, E; Sekar, V; Tomaka, F; Van Baelen, B; Vandevoorde, A; Vangeneugden, T | 1 |
| Dietz, B; Rajagopalan, R; Simpson, KN | 1 |
| Moreno, V; Valencia, ME | 1 |
| Mathew, M; McComsey, G; McGrath, D; Rightmire, A; Wirtz, V; Yang, R | 1 |
| Aarons, L; Back, D; Boffito, M; Davies, G; Dickinson, L; Else, L; Khoo, S; Pozniak, A; Waters, L | 1 |
| Aboulker, JP; Bentata, M; Brun-Vézinet, F; Capitant, C; Chazallon, C; Descamps, D; Katlama, C; Landman, R; Peytavin, G; Pialoux, G; Yéni, P | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Antinori, A; Antonucci, F; Carosi, G; Castelnuovo, F; De Luca, A; Di Perri, G; Esposito, R; Lapadula, G; Lazzarin, A; Maggiolo, F; Maserati, R; Migliorino, G; Paraninfo, G; Quirino, T; Rizzardini, G; Torti, C | 1 |
| Chen, CY; Grinspoon, SK; Hadigan, CM; Joy, T; Liebau, JG; Makimura, H; Robbins, GK; Stanley, TL; Thomas, BJ; Weise, SB | 1 |
| Lötsch, J; von Hentig, N | 1 |
| Krishna, G; Ma, L; Martinho, M; McLeod, J; Moton, A; Seiberling, M | 1 |
| Anderson, PL; Clay, PG; Glaros, AG; McRae, M | 1 |
| Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Anderson, PL; Aquilante, CL; Bushman, LR; Gardner, EM; MaWhinney, S; McDaneld, P; Predhomme, J; Ray, M; Zheng, JH | 1 |
| Chetchotisakd, P | 1 |
| Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| McCoy, C; Pollack, TM; Stead, W | 1 |
| Belsey, E; Berzins, B; Dube, MP; Fichtenbaum, C; Guaraldi, G; Mitchell, C; Murphy, RL; Stein, JH; Torriani, F; Zala, C | 1 |
| Andersson, MC; Böttiger, Y; Flamholc, L; Gisslén, M; Hagberg, L; Josephson, F; Ormaasen, V; Sönnerborg, A; Vesterbacka, J | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Bickel, M; Brodt, R; Haberl, A; Khaykin, P; Kurowski, M; Moesch, M; Nisius, G; Stephan, C; von Hentig, N | 1 |
| Cedeño, S; Clotet, B; Deig, E; Maria Llibre, J; Miranda, C; Moltó, J; Negredo, E; Valero, S; Valle, M | 1 |
| Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Prosperi, M; Ragazzoni, E | 1 |
| Dronda, F; Hernández, B; Moreno, S | 1 |
| Gatell, JM; Zamora, L | 1 |
| Boix, V; Merino, E; Portilla, J; Reus, S | 1 |
| Anta, L; Garrido, C; Mendoza, CD; Poveda, E; Soriano, V; Treviño, A | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Carper, MJ; Lei, X; Ramanadham, S; Richmond, SR; Yarasheski, KE; Zhang, S | 1 |
| Caso, G; Darras, F; Gelato, MC; McNurlan, MA; Mileva, I; Mynarcik, DC | 1 |
| Hylemon, PB; Li, X; Liang, G; Pandak, WM; Studer, EJ; Wang, G; Xiao, J; Zha, W; Zhou, H | 1 |
| Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N | 1 |
| Desai, PB; Hariparsad, N; Mugundu, GM | 1 |
| Ciurlionis, R; Degoey, DA; Kempf, DJ; Klein, LL; Marsh, K; Randolph, JT; Spear, B; Waring, JF | 1 |
| Anderson, A; Gendelman, HE; McMillan, J; Miller, R; Nowacek, AS; Rabinow, B | 1 |
| Burger, DM; Faraj, D; Gelinck, L; Kroon, F; Kuks, PF; Richter, C; Van der Ende, ME; Van der Ven, A; van Luin, M; Van Schaik, RH; Visser, M; Wit, FW | 1 |
| Asensi, V; Carmena, J; Cartón, JA; de la Fuente, B; Echevarría, S; Esteban, H; Flores, J; González-García, J; Mahillo, B; Mariño, AI; Minguez, C; Moyano, B; Ocampo, A; Ribera, E; Rubio, R; Sepúlveda, MA; Serrano, L; Serrano, O; Vicent, R; Zarraga, M | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Agarwala, S; Bertz, R; Dragone, J; Eley, T; Li, T; Mahnke, L; Persson, A; Xu, X; Zhu, L | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Calvez, V; Katlama, C; Lambert-Niclot, S; Machouf, N; Marcelin, AG; Murphy, RL; Peytavin, G; Simon, A; Soulie, C; Thomas, R; Wirden, M | 1 |
| Bendayan, R; Kis, O; Ramaswamy, M; Zastre, JA | 1 |
| Auclair, M; Bastard, JP; Boccara, F; Capeau, J; Caron-Debarle, M; Cohen, A; Lefèvre, C; Prot, M | 1 |
| Bierman, WF; Danner, SA; Jansen, G; Scheffer, GL; Scheper, RJ; Schoonderwoerd, A; van Agtmael, MA | 1 |
| Amin, J; Boyd, M; Carey, D; Emery, S; Petoumenos, K | 1 |
| Bellos, N; Dejesus, E; Murphy, D; Patel, LG; Ross, LL; Shaefer, MS; Squires, KE; Wannamaker, PG; Young, B; Zhao, HH | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Balogh, A; Biguenet, S; Carosi, G; Delfraissy, JF; Ghosn, J; Lazzarin, A; Leleu, G; Moreno, S; Pialoux, G; Pokrovsky, V; Sanz-Moreno, J; Vandeloise, E | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Hesse, K | 1 |
| Antoine, B; Capeau, J; Chapron, C; Kadiri, S; Leroyer, S; Quette, J; Vatier, C | 1 |
| Balkundi, S; Bronich, T; Gendelman, HE; Kabanov, AV; Kanmogne, G; Martinez-Skinner, A; McMillan, J; Mosley, RL; Nowacek, AS; Roy, U | 1 |
| Absalon, J; Johnson, M; McGrath, D; Sheppard, L; Squires, KE; Uy, J; Yang, R | 1 |
| Anderson, PL; Wempe, MF | 1 |
| Curto, J; del Rio, L; Domingo, P; Ferrer, E; Gatell, JM; Martínez, E; Negredo, E; Ordóñez, J; Podzamczer, D; Ribera, E; Rosales, J; Saumoy, M | 1 |
| Alaeus, A; Heeg, B; Lescrauwaet, B; Neubauer, A; Sennfält, K; Thuresson, PO | 1 |
| Callebaut, C; Cihlar, T; Hruz, PW; Koster, J; Tsai, L; Xu, L; Yan, Q | 1 |
| Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Daudon, M; De Castro, N; Glotz, D; Pillebout, E; Scemla, A; Verine, J; Viglietti, D | 1 |
| Benson, CA; Bolivar, H; Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Godfrey, C; Jahed, NC; Katzenstein, D; Mollan, K; Myers, L; Pappa, KA; Patterson, K; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| Borland, J; Chen, S; Lou, Y; Min, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T | 1 |
| Gold, WL; Koblic, PM; la Porte, CJ; Lee, TC | 1 |
| Bertz, R; Chung, E; Eley, T; Mahnke, L; Persson, A; Xu, X; Yones, C; Zhang, J | 1 |
| Burger, DM; Hamers, RL; van den Berk, GE; Welzen, ME | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| Azria, E; Crenn-Hebert, C; Ferreira, C; Floch-Tudal, C; Herinomenzanahary, E; Mandelbrot, L; Mazy, F; Meier, F; Peytavin, G; Treluyer, JM | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Barassi, A; Brandolini, M; Cusato, M; D'Arminio Monforte, A; Gulminetti, R; Maserati, R; Melzi D'Eril, GV; Regazzi, M; Sighinolfi, L; Tinelli, C; Villani, P | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Frankel, JK; Packer, CD | 1 |
| Bertz, R; Botes, M; Child, M; Conradie, F; Eley, T; Hu, W; Josipovic, D; McGrath, D; Osiyemi, O; Vandeloise, E; Wirtz, V; Zorrilla, C | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Aldrovandi, G; Brundage, RC; Fenton, T; Fletcher, CV; Graham, B; Kiser, JJ; Mofenson, LM; Rutstein, RM; Samson, P; Schnittman, S; Smith, E | 1 |
| Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Amara, A; Back, D; Boffito, M; Gazzard, B; Higgs, C; Jackson, A; Khoo, S; Moyle, G; Seymour, N | 1 |
| Crutchley, RD; Hochreitter, J; Ma, Q; Morse, GD; Sulaiman, A | 1 |
| Arikan, D; Bertz, R; Coumbis, J; Farajallah, A; Stonier, M; Wu, Y; Xu, X; Zhang, J; Zhu, L | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Alnouti, Y; Bathena, SP; Gautam, N; Gendelman, HE; Huang, J; McMillan, J; Roy, U | 1 |
| Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L | 1 |
| Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
| Andrews, S; Carlson, GA; Hanamsagar, R; Huang, Y; Ikezu, T; Kiyota, T; Lan, X; Peng, H; Swindells, S; Zheng, JC | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Alvarez Del Vayo Benito, C; Falcon-Neyra, L; León Leal, JA; Lopez-Cortes, LF; Neth, O; Obando, I; Ruiz-Valderas, R | 1 |
| Ananthakrishnan, S; Garg, A; Levine, D | 1 |
| Ashton, M; Ekvall, H; Flamholc, L; Gisslén, M; Ormaasen, V; Röshammar, D; Simonsson, US; Vesterbacka, J; Wallmark, E | 1 |
| Bogachus, LD; Turcotte, LP | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S | 1 |
| Andrade-Villanueva, J; Cheng, AK; Chuck, SL; Clotet, B; Clumeck, N; Lamarca, A; Liu, YP; Margot, N; Molina, JM; Zhong, L | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Appel, DI; Markowitz, JS; Peloquin, CA; Peterson, YK; Rhoades, JA; Zhu, HJ | 1 |
| Balkundi, S; Bronich, T; Chen, H; Gendelman, HE; Kabanov, AV; Kanmogne, G; Liu, X; Martinez-Skinner, A; McMillan, J; Mosley, RL; Nowacek, AS; Roy, U; Veerubhotla, RS | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Deeks, ED | 1 |
| Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Arnaiz, JA; Clotet, B; Cruceta, A; Dalmau, D; Diaz-Brito, V; Domingo, P; García, F; Gatell, JM; Knobel, H; León, A; Peraire, J | 1 |
| Aberg, JA; De La Rosa, G; Falcon, R; Gupta, SK; Landay, A; Overton, ET; Ryan, R; Sax, PE; Tebas, P | 1 |
| Chiarella, J; DeGrosky, M; Kozal, M; Lataillade, M; Moreno, E; Seekins, D; Simen, B; St John, E; Uy, J; Yang, R | 1 |
| Fernandez, VA; Reiser, IW; Spitalewitz, S; Thomas, DB | 1 |
| Anderson, PL; Aquilante, CL; Castillo-Mancilla, JR; Kile, DA; MaWhinney, S; Rower, JE | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Butcher, D; Farajallah, A; Hu, W; Juethner, S; McDonald, C; McGrath, D; Moyle, G; Uy, J; Wirtz, V | 1 |
| Cenderello, G; Di Biagio, A; Loregian, A; Pagni, S; Palù, G; Rosso, R; Sormani, MP; Viscoli, C | 1 |
| Aguilar-Bernier, M; Del Boz, J; Fernández-Morano, T; Fúnez-Liébana, R | 1 |
| Bloom, A; Brown, TT; Daar, ES; Fedarko, N; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C | 1 |
| Baran, RW; Beck, EJ; Collomb, D; Dietz, B; Simpson, KN; Van de Steen, O | 1 |
| Antonijoan, RM; Barbanoj, MJ; Cedeño, S; Clotet, B; Domingo, P; Estévez, JA; Mangues, MA; Moltó, J; Puntes, M; Tuneu, L; Valle, M | 1 |
| Demarchi, IG; Ferreira, IC; Lonardoni, MV; Silveira, TG | 1 |
| Arnáez, P; Esteban, M; García-Arriaza, J; Gómez, CE; Jiménez, JL; Muñoz-Fernández, MÁ | 1 |
| Alnouti, Y; Balkundi, S; Bronich, T; Gautam, N; Gendelman, HE; Gorantla, S; Kabanov, A; Kanmogne, GD; Liu, X; McMillan, J; Poluektova, L; Roy, U; Singh, S; Smith, N; Zhou, Y | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Alnouti, Y; Balkundi, S; Dash, PK; Gelbard, HA; Gendelman, HE; Gorantla, S; McMillan, J; Mosley, RL; Poluektova, LY; Roy, U | 1 |
| Adorni, F; Galli, M; Giacomet, V; Mameli, C; Rusconi, S; Viganò, A; Viganò, O; Zuccotti, GV | 1 |
| Pommer, P | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Aleixo, MJ; Camacho, RJ; Cavaco-Silva, J; Cunha, C; Faria, D; Gomes, P; Gonçalves, Mde F; Valadas, E; Van Laethem, K; Vandamme, AM | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Austin, R; Back, D; Boffito, M; Davies, G; Dickinson, L; Khoo, S; Owen, A; Schipani, A | 1 |
| Brockmeyer, N; Dupke, S; Eychenne, JL; Jansen, K; Jimenez-Exposito, MJ; Nakonz, T; Pugliese, P; Sönnerborg, A; Svedhem, V; Thalme, A | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B | 1 |
| Margolis, DA; Pakes, GE; Ross, LL; Santiago, L; Shaefer, MS; Sloan, LM; Squires, KE; Wine, BC; Young, B; Zhao, HH | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Montrucchio, C; Simiele, M; Tettoni, MC; Trentini, L | 1 |
| Katlama, C; Lê, MP; Peytavin, G; Soulie, C; Stitou, H | 1 |
| Collier, AC; Daar, ES; Fischl, MA; Haas, DW; Mollan, K; Morse, GD; Ribaudo, HJ; Sax, PE; Tierney, C | 1 |
| Balamane, M; Bosch, RJ; Collier, AC; Daar, ES; Fischl, MA; Katzenstein, D; Lalama, CM; Mollan, K; Sax, PE; Tierney, C | 1 |
| Butterton, JR; Feng, HP; Hughes, EA; Hulskotte, EG; O'Mara, E; Treitel, MA; van Zutven, MG; Wagner, JA; Xuan, F; Youngberg, SP | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Äbelö, A; Ashton, M; Barrail-Tran, A; Bergstrand, M; Calcagno, A; D'Avolio, A; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Tarning, J; Vigan, M | 1 |
| Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN | 1 |
| Dabis, F; De Wit, S; El-Sadr, W; Kirk, O; Law, MG; Lundgren, JD; Monforte, Ad; Phillips, AN; Pradier, C; Reiss, P; Ryom, L; Sabin, CA; Weber, R; Worm, SW | 1 |
| Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Cauda, R; Ciccarelli, N; Cingolani, A; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Farina, S; Mondi, A; Murri, R; Navarra, P; Sidella, L; Tamburrini, E | 1 |
| Bigliano, P; Bonora, S; Bramato, C; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Libanore, V; Motta, I; Orofino, G; Orsucci, E; Salassa, B; Simiele, M; Tettoni, MC | 1 |
| Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Bertz, RJ; Chung, E; Grasela, D; McGrath, D; Persson, A; Zhang, J; Zhu, L | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B | 1 |
| Bonfanti, P; Bonizzoni, E; Croce, D; Foglia, E; Porazzi, E; Restelli, U; Ricci, E; Rizzardini, G; Scolari, F | 1 |
| Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M | 1 |
| Baril, JG; Fournier, C; Higgins, N; Lalonde, R; Sheehan, NL; Thibeault, D; Thomas, R | 1 |
| Cahn, P; Sued, O | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
| Gendelman, HE; Liu, H; Martinez-Skinner, AL; McMillan, JM; Veerubhotla, RS; Xiong, H; Yu, F | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Barlet, MH; Brockmeyer, NH; Esser, S; Jimenez-Exposito, MJ; Michalik, C; Nakonz, T; Pugliese, P; Svedhem-Johansson, V; Thalme, A | 1 |
| Alnouti, Y; Balkundi, S; Fox, HS; Gautam, N; Gendelman, HE; Guo, D; Lamberty, B; Liu, XM; McMillan, J; Morsey, B; Puligujja, P; Roy, U; Smith, N | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Karolia, Z; Moyle, G; Ringner-Nackter, L; Seymour, N; Yapa, MH | 1 |
| Dewhurst, S; DiFrancesco, R; Gelbard, HA; Gendelman, HE; Hochreiter, JS; Ma, Q; Maggirwar, SB; Morse, GD; Peterson, DR; Schifitto, G | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Bertz, R; Botes, M; Conradie, F; Eley, T; Hardy, H; Huang, SP; Josipovic, D; McGrath, D; Osiyemi, O; Zorrilla, CD | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Teruya, K | 1 |
| Antinori, A; Castagna, A; d'Arminio Monforte, A; Galli, L; Gianotti, N; Lazzarin, A; Maserati, R; Quiros-Roldan, E; Salpietro, S; Torti, C | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Arai, M; Satoh, M; Tanaka, H; Tomoda, Y; Wada, T; Yago, K | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Bhavani, PK; Chandrasekaran, C; Hemanth Kumar, AK; Raja, K; Ramachandran, G; Srinivasan, R; Sudha, V; Swaminathan, S; Venkatesh, S | 1 |
| Lambert, JS; Macken, A; Mallon, PW; O'Halloran, JA; O'Halloran, RM; Sheehan, GJ; Tinago, W | 1 |
| Angel, JB; Baril, J; Conway, B; Ferko, N; Giguère, P; Hollmann, S | 1 |
| Bendayan, R; Cameron, W; Chan, GN; la Porte, C; Robillard, KR; Zhang, G | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T | 1 |
| Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
| Haberl, A; Johnson, M; Walmsley, S | 1 |
| Antoniadou, A; Detsika, M; Hatzakis, A; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Paraskevis, D; Petrikkos, G; Protopapas, K; Sypsa, V | 1 |
| Afonso, P; Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Daar, ES; Haas, DW; Johnson, DH; McLaren, PJ; Morse, GD; Ritchie, MD; Venuto, C | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Desjeux, JF; Dossou-Yovo, F; Eto, B; Limas-Nzouzi, N; Mamadou, G; Miantezila, J; Soudy, ID | 1 |
| Mishra, T; Shrivastav, PS | 1 |
| Autran, B; Caby, F; Carcelain, G; Costagliola, D; Fourati, S; Guiguet, M; Guihot, A; Hattab, S; Katlama, C; Marcelin, AG | 1 |
| Fletcher, CV; Podany, AT; Robbins, BL; Winchester, LC | 1 |
| Acosta, EP; Armstrong, WS; Arrendale, RF; Delille, CA; Easley, KA; Lennox, JL; Marconi, VC; Ofotokun, I; Pruett, ST; Sheth, AN; Vunnava, A | 1 |
| Bastow, B; Borowski, L; Kearney, M; Mailliard, RB; McKinnon, JE; Mellors, JW; Rinaldo, CR; Roper, JM; Swindells, S; Wiegand, A; Wilkin, TJ | 1 |
| Back, DJ; Brennan, M; Coulter-Smith, S; Else, LJ; Jackson, V; Khoo, SH; Lambert, JS | 1 |
| Arends, JE; Burger, DM; de Kanter, CT; Hoepelman, AI; Jacobs, BS; van Elst-Laurijsen, DH; van Maarseveen, EM; Verwey-van Wissen, CP | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Burger, D; Colbers, A; Giaquinto, C; Gingelmaier, A; Hawkins, D; Hidalgo-Tenorio, C; Ivanovic, J; Kabeya, K; Lambert, J; Moltó, J; Rockstroh, J; Sadiq, ST; Taylor, G; van der Ende, M; Weizsäcker, K; Wyen, C | 1 |
| Allegra, S; Bonora, S; Calcagno, A; Carcieri, C; Cusato, J; D'Avolio, A; Di Perri, G; Sciandra, M; Simiele, M; Trentini, L | 1 |
| Antinori, A; Carini, E; Castagna, A; D'Arminio Monforte, A; Di Biagio, A; Galli, L; Lazzarin, A; Montella, F; Nozza, S; Rusconi, S; Spagnuolo, V; Vinci, C | 1 |
| Audagnotto, S; Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; De Rosa, FG; Di Perri, G; Pagani, N; Simiele, M | 1 |
| Collier, AC; Daar, ES; Fischl, M; Ma, Q; Mollan, K; Morse, GD; Sax, PE; Smith, KY; Tierney, C; Venuto, CS | 1 |
| Batard, ML; Bernard-Henry, C; Cheneau, C; De Mautort, E; Fafi-Kremer, S; Gantner, P; Koeppel, C; Muret, P; Partisani, M; Priester, M; Rey, D; Sueur, C | 1 |
| Atrio, J; Cherala, G; DuBois, BN; Stanczyk, FZ | 1 |
| Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Riva, A; Rizzardini, G | 1 |
| Alnouti, Y; Balkundi, S; Fox, HS; Gautam, N; Gendelman, HE; Liu, XM; McMillan, J; Puligujja, P; Thakare, R | 1 |
| Farajallah, A; Hardy, H; Kaplita, S; McGrath, SJ; Moyle, GJ; Ward, D | 1 |
| Bade, AN; Baldridge, HM; Balkundi, SS; Dash, PK; Dimitrov, DS; Feng, Y; Gendelman, HE; Gorantla, S; Hilaire, JR; Kendrick, LM; Liu, XM; McMillan, JM; Poluektova, LY; Puligujja, P; Wang, Y; Ying, T; Zhang, G | 1 |
| Alves, ÉAR; Borges, TK; de Miranda, MG; Magalhães, KG; Muniz-Junqueira, MI | 1 |
| Azwa, I; Boettiger, DC; Bui, HV; Durier, N; Heng Sim, BL; Law, M; Nguyen, VK; Ruxrungtham, K | 1 |
| Costarelli, S; Di Giambenedetto, S; Di Pietro, M; Lorenzotti, S; Maggiolo, F; Postorino, MC; Prosperi, M; Quiros-Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
| Bourgeois-Moine, A; Bourse, P; Calvez, V; Damond, F; Descamps, D; Dommergues, M; Duro, D; Faucher, P; Ichou, H; Landman, R; Lariven, S; Lê, MP; Legac, S; Mandelbrot, L; Matheron, S; Meier, F; Mortier, E; Peytavin, G; Soulié, C; Tubiana, R; Valantin, MA | 1 |
| Campbell, L; Cheserem, E; Engler, B; Hamzah, L; Naftalin, C; Post, FA; Taylor, C; Wandolo, E | 1 |
| Minaeva, SV; Moshkovich, GF | 1 |
| Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A | 1 |
| Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G | 1 |
| Córdoba Iturriagagoitia, A; Mitxelena Ezeiza, J; Santesteban Muruzábal, R; Yanguas Bayona, I | 1 |
| Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L | 1 |
| Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Ferraris, L; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Minisci, D; Molinari, L; Riva, A; Rizzardini, G | 1 |
| Borghetti, A; Cauda, R; Ciccarelli, N; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Mondi, A | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Adeyemo, T; Akanmu, AS; Awolola, A; Bello, FO; Kanki, PJ; Lesi, F; Ogunsola, FT; Okonkwo, P; Okwuegbuna, K; Oloko, K | 1 |
| Araínga, M; Dash, P; Gendelman, HE; Gorantla, S; McMillan, J; Mosley, RL; Palandri, D; Poluektova, L; Puligujja, P | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Arce, PM; Biguenet, S; Cambilargiu, D; Correll, T; Donati, AP; Hardy, H; Lissens, J; Strehlau, R; Yang, R | 1 |
| Ascoli-Bartoli, T; Bellelli, V; Bianchi, L; Ceccarelli, G; d'Ettorre, G; De Girolamo, G; Giustini, N; Mastroianni, CM; Serafino, S; Vullo, V; Zaccarelli, M | 1 |
| Henry, K; LaMarca, A; Ross, LL; Schneider, S; Shaefer, MS; Squires, KE; Tashima, K; Young, B; Zhao, HH | 1 |
| Bhatti, L; DeJesus, E; Edelstein, H; Margolis, DA; Ross, LL; Shaefer, MS; Small, CB; Weinberg, WG; Wohl, DA; Zhao, HH | 1 |
| Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
| Anderson, J; Barbour, A; Conway, K; Dermont, S; deRuiter, A; Dwyer, E; Flanagan, S; Hawkins, D; Hay, P; McKendry, A; Mulka, L; Perry, ME; Rodgers, M; Roedling, S; Sabin, CA; Sarner, L; Shah, R; Stevenson, J; Taylor, GP; Williams, E; Wood, C | 1 |
| Ding, Y; Duan, J; Freeling, J; Ho, RJ; Koehn, J | 1 |
| Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P | 1 |
| Flandre, P | 1 |
| Antinori, A; Baakili, A; Gatell, JM; Girard, PM; Klauck, I; Osiyemi, O; Pozniak, A; Serrano, O; Sevinsky, H; van Lunzen, J | 1 |
| Brouillette, M; Farr, AM; Johnston, SS; Ritchings, C; Rosenblatt, L | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N | 1 |
| Alfaro, RM; Calderón, MM; Kovacs, JA; Kumar, P; McManus, M; Pau, AK; Penzak, SR | 1 |
| Bharti, S; Hirsch, B; Malhotra, P | 1 |
| Antela, A; Jiménez-Expósito, MJ; Knechten, H; Kuhlmann, B; Rocha-Pereira, N; Santos, J; Teófilo, E | 1 |
| Colella, E; Di Cristo, V; Franzetti, M; Galli, M; Giacomelli, A; Oreni, L; Ridolfo, AL; Rusconi, S | 1 |
| Baugh, BP; Coate, B; Dayaram, YK; De La Rosa, G; Overton, ET; Perniciaro, A; Ryan, R; Tebas, P | 1 |
| Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A | 1 |
| Antinori, A; Bigoloni, A; Borderi, M; Caramatti, G; Castagna, A; D'Arminio Monforte, A; Di Biagio, A; Di Giambenedetto, S; Galli, L; Gibellini, D; Guaraldi, G; Lazzarin, A; Montella, F; Rusconi, S; Spagnuolo, V | 1 |
| Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
| Durante, W; Durante, ZE; Liu, XM; Peyton, KJ | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G | 1 |
| Alhalaweh, A; Bergström, CAS; Taylor, LS | 1 |
| Díez-García, LF; Gálvez-Contreras, MC; Romero-León, JM | 1 |
| Assoumou, L; Benalycherif, A; Cabié, A; Costagliola, D; Duvivier, C; Girard, PM; Joly, V; Lambert-Niclot, S; Landman, R; Marcelin, AG; Peytavin, G; Pialoux, G; Samri, A; Slama, L; Valin, N | 1 |
| Ferretti, F; Mora-Peris, B; Stevens, E; Taylor, S; Underwood, J; Winston, A | 1 |
| Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A | 1 |
| Kiertiburanakul, S; Numthavej, P; Puangpetch, A; Sukasem, C; Thakkinstian, A; Wongprikorn, A | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
| Bigoloni, A; Caramatti, G; Castagna, A; Cattaneo, D; Cinque, P; Ferretti, F; Fuchs, D; Galli, L; Gerevini, S; Gisslen, M; Lazzarin, A; Longo, V; Passeri, L; Spagnuolo, V; Zetterberg, H | 1 |
| Bertz, RJ; Brüggemann, RJ; Burger, DM; Chung, E; Colbers, A; Hruska, MW; Sims, K; Uy, J; Vakkalagadda, B; van Schaik, RH; Xu, X; Zhu, L | 1 |
| Domingo, P; Vidal, F | 1 |
| Apornpong, T; Avihingsanon, A; Banchongkit, S; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chaivooth, S; Chetchotisakd, P; Cooper, DA; Emery, S; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Kiertiburanakul, S; Klinbuayaem, V; Leerattanapetch, N; Mekviwattanawong, S; Munsakul, W; Nimitvilai, S; Phanuphak, P; Prasithsirikul, W; Ruxrungtham, K; Techapornroong, M | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Ambrose, P; Benson, CA; Devaraj, C; Ezhilarasi, C; Jenks, JD; Kumarasamy, N; Poongulali, S; Yepthomi, T | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Beniowski, M; Cozzi-Lepri, A; Duvivier, C; Edwards, S; Falconer, K; Hassoun, G; Kuznetsova, A; Kuzovatova, E; Laut, K; Llibre, JM; Losso, M; Maltez, F; Mitsura, V; Mocroft, A; Paredes, R; Pedersen, C; Ristola, M; Stellbrink, HJ; Szlavik, J; Vullo, V | 1 |
| Burger, DM; Colbers, EP; de Kanter, CT; Drenth, JP; Smolders, EJ; Velthoven-Graafland, K | 1 |
| Bani-Sadr, F; Gantner, P; Garraffo, R; Jovelin, T; Pugliese, P; Rey, D; Roger, PM; Treger, M | 1 |
| Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
| Benet, LZ; Faber, KP; Frassetto, LA; Kadiyala, P; Wu, HF; Xu, X; Yago, MR | 1 |
| Antinori, A; Borghetti, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Francisci, D; Grima, P; Latini, A; Madeddu, G; Mondi, A; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Listowsky, I; Roy-Chowdhury, J; Roy-Chowdhury, N; Wolkoff, AW | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Belmonti, S; Castagna, A; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Boffito, M; Dicker, IB; Grasela, D; Hüser, A; Hwang, C; Keicher, C; Krystal, M; Lataillade, M; Ravindran, P; Ray, N; Schürmann, D; Sevinsky, H; Sobotha, C; Xiao, H | 1 |
| Antoniou, T; Bayoumi, AM; Burchell, AN; Cooper, C; Hogg, RS; Klein, MB; Loutfy, M; Machouf, N; Montaner, JS; Raboud, J; Szadkowski, L; Tsoukas, C; Walmsley, S; Wong, A | 1 |
| Chawana, TD; Gandhi, M; Horng, H; Katzenstein, D; Louie, A; Metcalfe, J; Nathoo, K; Ngara, B; Nhachi, CFB | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Broadhurst, R; Gugsa, S; Heller, T; Hosseinipour, MC; Lim, R; Ngongondo, M; Ongubo, DM; Phiri, S; Speight, C; Stanley, CC; Tembo, P; Tweya, H | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Joly, V; Landman, R; Marcelin, AG; Perrier, M; Todesco, E; Visseaux, B; Yazdanpanah, Y | 1 |
| Chen, JS; DiMeglio, LA; Geffner, ME; Jacobson, D; Jao, J; Karalius, B; McFarland, EJ; Miller, TL; Mirza, A; Patel, K; Silio, M; Van Dyke, RB; Yu, W | 1 |
| Hanna, GJ; Joshi, SR; Krystal, M; Lataillade, M; Lee, S; Stock, DA; Zhou, N | 1 |
| Cambilargiu, D; Correll, TA; Cotton, MF; Gonzalez-Tome, MI; Klauck, I; Liberty, A; Lissens, J; Pikora, C; Torres-Escobar, I; Zaru, L | 1 |
| Correll, TA; Eley, T; Pikora, C; Sevinsky, H; Wang, R; Xu, X; Zaru, L | 1 |
| Lundgren, J; Mocroft, A; Ryom, L | 1 |
| Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
| Mantena, BPV; Mantripragada, MKVVN; Nutulapati, VVS; Rao, SV | 1 |
| Altman, RB; Alvarellos, M; Guillemette, C; Klein, TE | 1 |
| Antinori, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Avino, A; d'Ettorre, G; De Luca, A; Del Pin, B; Di Giambenedetto, S; Fabbiani, M; Focà, E; Francisci, D; Gagliardini, R; Grima, P; Latini, A; Lombardi, F; Madeddu, G; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Gohel, S; Kumar, A; Letendre, S; Patel, AK; Patel, KK | 1 |
| Alvarenga, DLR; Alves, ÉAR; Calzavara-Silva, CE; de Oliveira, JG; Fiuza, JA; Gaze, ST; Oliveira, RC; Pascoal-Xavier, MA; Silva, AHDS | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Castelli, F; Castelnuovo, F; Cusato, J; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Trentini, L | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Castagna, A; Cauda, R; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Cerveny, L; Durisova, M; Ptackova, Z; Staud, F | 1 |
| Bandera, A; Clerici, M; Fenizia, C; Giannattasio, C; Gori, A; Maloberti, A; Masetti, M; Muscatello, A; Sabbatini, F; Soria, A; Squillace, N; Trabattoni, D | 1 |
| Crespo, M; Esteban, H; Gutiérrez, F; Hernández-Quero, J; Iribarren, JA; Mariño, A; Pasquau, J; Pérez-Molina, JA; Pérez-Valero, I; Rivero, A; Rubio, R; Santos, J; Sanz, J; Terrón, A | 1 |
| Gao, Y; Indulkar, AS; Raina, SA; Taylor, LS; Zhang, GGZ | 1 |
| Chu, GJ; Evans, L; Henderson, C; Howlin, K; Murad, A | 1 |
| Ho, RJY; Koehn, J; Kraft, JC; McConnachie, LA; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Brogan, AJ; Davis, AE; Goodwin, B | 1 |
| Avihingsanon, A; Bowonwattanuwong, C; Chuasuwan, B; Duereh, M; Gatechompol, S; Hiransuthikul, A; Karachot, B; Manamuti, C; Ruxrungtham, K; Sawpitiporn, M; Sophonphan, J; Techatanawat, I; Thammajaruk, N | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Antinori, A; Carrara, S; Cozzi Lepri, A; D'arminio Monforte, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Giacometti, A; Lichtner, M; Marchetti, G; Sighinolfi, L | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Chmielinska, JJ; ElZohary, L; Kramer, JH; Mak, IT; Weglicki, WB | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| El-Hage, N; Karuppan, MKM; Kashanchi, F; Lapierre, J; Ojha, CR; Pawitwar, S; Rodriguez, M | 1 |
| Castelnuovo, B; Kaimal, A; Kiragga, A; Laker, EAO; Lamorde, M; Musubire, A; Nabaggala, MS; Nalwanga, D; Ratanshi, RP | 1 |
| Avihingsanon, A; Bunupuradah, T; Burger, DM; Chetchotisakd, P; Emery, S; Kiertiburanakul, S; Punyawudho, B; Ruxrungtham, K; Singkham, N; Thammajaruk, N | 1 |
| Cecka, F; Cerveny, L; Huliciak, M; Martinec, O; Staud, F; Vokral, I | 1 |
| Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD | 1 |
| Basilua, JM; Pochart, P | 1 |
| Auclair, M; Capeau, J; Fellahi, S; Garcia, M; Guénantin, AC | 1 |
| Bulmahn, JC; He, GS; Kutscher, HL; Mahajan, SD; Prasad, PN; Singh, A | 1 |
| Aweeka, F; Baker, P; Berzins, B; Cohn, SE; Coombs, R; Coughlin, K; Cramer, YS; Gingrich, D; Godfrey, C; Haas, DW; Moran, LE; Rosenkranz, SL; Scarsi, KK; Zorrilla, CD | 1 |
| Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS | 1 |
| Demirkan, K; Fırat, O; Yalçın, N | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Stray-Pedersen, B; Zvada, S | 1 |
| Alves, CR; Bozza, FA; Bozza, PT; Cardoso Soares, V; Carels, N; da Silva Gomes Dias, S; de Freitas, CS; Ferreira, AC; Fintelman-Rodrigues, N; Matos, AR; Mattos, M; Miranda, MD; Ribeiro Lima, C; Sacramento, CQ; Siqueira, MM; Souza da Silva, F; Souza, TML; Temerozo, JR | 1 |
| Abbasian, L; Davoudi-Monfared, E; Ghaderkhani, S; Ghiasvand, F; Hasannezhad, M; Khalili, H; Mohammadi, M; Nabiee, M; Nourian, A; Rahmani, H; Sadeghi, S; Seifi, A; Yekaninejad, MS | 1 |
| Adeagbo, BA; Adebiyi, AO; Adefuye, BO; Akinloye, A; Bolaji, OO; Fagbamigbe, AF; Fowotade, A; Happi, C; Ladipo, OT; Ojo, TO; Olagunju, A; Olagunju, OI; Olagunoye, A; Onayade, A; Owen, A; Rannard, S | 1 |
| Agide, FD; Mohraz, M; Nikfar, S; Tigabu, BM | 1 |
| Alomar, FA; Bidasee, KR; Dash, PK; Gendelman, HE; Gorantla, S; McMillan, JM; Tian, C | 1 |
| Abideen, G; Adewumi, OO; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, A; Busari, AA; Hassan, OO; Kadri, MR; Oreagba, IA; Usman, SO | 1 |
| Dallocchio, RN; De Vito, A; Delogu, G; Dessì, A; Madeddu, G; Serra, PA | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Chawana, TD; Gandhi, M; Katzenstein, D; Kuncze, K; Louie, A; Metcalfe, J; Nathoo, K; Ngara, B; Nhachi, CFB; Okochi, H | 1 |
| Alimohamadi, Y; Fard, SR; Kalantari, S; Maleki, D; Minaeian, S; Taher, MT; Yassin, Z | 1 |
| Budiman, F; Ivan, I; Juliawati, DJ; Ridjab, DA | 1 |
| Best, BM; Capparelli, E; Chakhtoura, N; Eke, AC; Kreitchmann, R; Mirochnick, M; Shapiro, D; Stek, A; Wang, J | 1 |
| Alhalaweh, A; Bergström, CAS; El Sayed, M | 1 |
| Bunglawala, F; Cottura, N; Denti, P; Fabrega, F; Howarth, A; Kinvig, H; Lloyd, A; Montanha, MC; Siccardi, M; Waitt, C | 1 |
| Eugênio, E; Livinalli, A; Moraes, EL; Negrete, CL; Paes, RD; Serpa Osorio-de-Castro, CG; Sobreira da Silva, MJ | 1 |
| Tsanni, A | 1 |
| Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI | 1 |
| Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M | 1 |
| Adankie, BT; Aklillu, E; Amogne, W; Engidawork, E; Shibeshi, W; Tadesse, WT | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Castelnuovo, B; Lumu, I; Musaazi, J | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Campisi, J; Desprez, PY; Hughes, JB; Kuehnemann, C; Melov, S; Wiley, CD | 1 |
| Atkinson, H; Coghlan, H; Edgerton, J; Elsby, R; Hodgson, D; Outteridge, S | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Beltrami, M; Cattaneo, D; Gervasoni, C; Micheli, V; Pagano, S | 1 |
| Chikamoto, J; Hirata, M; Nagahara, M; Omori, H; Otoi, T | 1 |
| Atefi, N; Baghestani, A; Goodarzi, A; Khodabandehloo, N; Mahdi, Z; Najar Nobari, N; Riahi, T; Seirafianpour, F; Talebi Taher, M; Valizadeh, R | 1 |
24 review(s) available for atazanavir sulfate and ritonavir
| Article | Year |
|---|---|
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Review of atazanavir: a novel HIV protease inhibitor.
Topics: Administration, Oral; Animals; Atazanavir Sulfate; Contraindications; Drug Approval; Drug Interactions; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Patient Compliance; Pyridines; Randomized Controlled Trials as Topic; Ritonavir | 2005 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2005 |
Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir | 2007 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Atazanavir/ritonavir: a review of its use in HIV therapy.
Topics: Animals; Atazanavir Sulfate; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir | 2008 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir | 2008 |
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
[Efficacy of atazanavir in treatment-naive patients].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome | 2008 |
[Efficacy of atazanavir in simplification regimens].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
[Efficacy of atazanavir in rescue therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Dyslipidemias; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Oligopeptides; Patient Compliance; Point Mutation; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load | 2008 |
[Clinical utility of atazanavir].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Insulin Resistance; Oligopeptides; Patient Acceptance of Health Care; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load | 2008 |
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; Humans; Lipids; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Ritonavir | 2010 |
Atazanavir: in pediatric patients with HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Area Under Curve; Atazanavir Sulfate; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Topics: Atazanavir Sulfate; Drug Substitution; Drug Therapy, Combination; HIV Infections; Humans; Maintenance Chemotherapy; Oligopeptides; Protease Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Ritonavir | 2014 |
A systematic review of the use of atazanavir in women infected with HIV-1.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Pregnancy; Pyridines; Ritonavir; Sex Factors; Treatment Outcome; Viral Load | 2014 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Contemporary protease inhibitors and cardiovascular risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Risk Assessment; Ritonavir | 2018 |
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
Topics: Adult; Atazanavir Sulfate; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Electrocardiography; Humans; Long QT Syndrome; Lopinavir; Ritonavir; Saquinavir | 2021 |
158 trial(s) available for atazanavir sulfate and ritonavir
| Article | Year |
|---|---|
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Oligopeptides; Pilot Projects; Protease Inhibitors; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Failure | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2003 |
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Ritonavir; Spectrophotometry, Ultraviolet; Tenofovir | 2004 |
Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Clinical Chemistry Tests; Drug Monitoring; Drug Therapy, Combination; Hematologic Tests; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
PI monotherapy effective as maintenance.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Cholesterol, LDL; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides | 2005 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Topics: Adult; Atazanavir Sulfate; Blood Proteins; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome | 2006 |
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Approval; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Phenotype; Pyridines; Ritonavir; Treatment Outcome; Viral Load | 2006 |
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Salvage Therapy; Tenofovir; Treatment Failure | 2006 |
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Topics: Adult; Algorithms; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Patient Compliance; Pilot Projects; Pyridines; Ritonavir; RNA, Messenger; Viral Load | 2006 |
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Topics: Adipocytes; Adult; Atazanavir Sulfate; Cell Differentiation; Cross-Over Studies; Drug Combinations; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2006 |
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Topics: Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Oligopeptides; Pyridines; Rifampin; Ritonavir | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2007 |
Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2007 |
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Treatment Outcome | 2007 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Creatinine; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oligopeptides; Organophosphonates; Prognosis; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2007 |
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Matched-Pair Analysis; Metabolic Clearance Rate; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2007 |
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Topics: Adult; Aged; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Microbial Sensitivity Tests; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Stavudine; Viral Load; Withholding Treatment | 2008 |
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maternal-Fetal Exchange; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridines; Ritonavir | 2007 |
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Oligopeptides; Proportional Hazards Models; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Viremia | 2008 |
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Topics: Adult; Aged; Atazanavir Sulfate; Body Composition; Dyslipidemias; HIV Infections; HIV Protease Inhibitors; Humans; Insulin Resistance; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Treatment Outcome; Triglycerides | 2008 |
CASTLE study showed similar efficacy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2008 |
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Topics: Adult; Anti-HIV Agents; Anti-Ulcer Agents; Area Under Curve; Atazanavir Sulfate; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H2 Antagonists; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Pyrimidinones; Ranitidine; Ritonavir | 2008 |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2008 |
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Combinations; Drug Interactions; Female; Fluorobenzenes; Furans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oligopeptides; Organophosphates; Prospective Studies; Pyridines; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides | 2008 |
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Endothelium, Vascular; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lopinavir; Male; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome; Vasodilation | 2008 |
A king in the CASTLE? Optimum initial HIV protease inhibitor.
Topics: Atazanavir Sulfate; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Tablets; Viral Load | 2008 |
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2008 |
Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; HIV Infections; HIV Protease Inhibitors; HLA-DR Antigens; Humans; Longitudinal Studies; Male; Membrane Glycoproteins; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Saquinavir; T-Lymphocyte Subsets; Viral Load | 2008 |
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome | 2008 |
Low atazanavir concentrations in cerebrospinal fluid.
Topics: Adult; AIDS Dementia Complex; Atazanavir Sulfate; Blood-Brain Barrier; CD4 Lymphocyte Count; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2009 |
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; Treatment Outcome; Viremia; Young Adult | 2009 |
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.
Topics: Adult; Antitubercular Agents; Atazanavir Sulfate; Female; Gastrointestinal Tract; HIV Protease Inhibitors; Humans; Liver; Male; Oligopeptides; Pyridines; Rifampin; Ritonavir | 2009 |
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Topics: Adolescent; Adult; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fasting; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sulfonamides; Triglycerides; Young Adult | 2009 |
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Pyridines; Ritonavir; Stavudine | 2009 |
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lopinavir; Male; Middle Aged; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2009 |
Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Benzoxazines; Cross-Over Studies; Cyclopropanes; Drug Interactions; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Triazoles | 2009 |
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Prodrugs; Pyridines; Ritonavir; Sulfonamides | 2009 |
Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Pilot Projects; Pyridines; Ritonavir | 2010 |
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Ritonavir | 2011 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Random Allocation; Ritonavir; RNA, Viral; Viral Load; Virus Replication; Young Adult | 2010 |
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Sex Factors | 2011 |
Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.
Topics: Atazanavir Sulfate; Black or African American; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; HIV Protease Inhibitors; Humans; Kinetics; Male; Metabolic Clearance Rate; Metabolic Detoxication, Phase I; Microsomes, Liver; Molecular Structure; Oligopeptides; Oxidation-Reduction; Pyridines; Recombinant Proteins; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; United States | 2011 |
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Topics: Adolescent; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Viral Load; Young Adult | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Linear Models; Male; Middle Aged; Oligopeptides; Oxazines; Piperazines; Pyridines; Pyridones; Ritonavir; Young Adult | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Puerto Rico; Pyridines; Ritonavir; South Africa; United States; Viral Load | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
Topics: Adolescent; Atazanavir Sulfate; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Male; Oligopeptides; Pyridines; Ritonavir; South Africa; Treatment Outcome; United States; Young Adult | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2011 |
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Darunavir; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2011 |
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Atazanavir Sulfate; Biotransformation; Drug Therapy, Combination; Female; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Oligopeptides; Pyridines; Rifabutin; Ritonavir; Tuberculosis; Young Adult | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Limit of Detection; Lopinavir; Male; Middle Aged; Nonlinear Dynamics; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphorus Compounds; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Atazanavir Sulfate; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Oligopeptides; Post-Exposure Prophylaxis; Pyridines; Ritonavir; Zidovudine | 2012 |
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Darunavir; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Male; Medication Adherence; Oligopeptides; Pyridines; Quality of Life; Ritonavir; Surveys and Questionnaires | 2012 |
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; C-Reactive Protein; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Inflammation; Interleukin-6; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Over Studies; Healthy Volunteers; Humans; Lipids; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Ritonavir; Young Adult | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pharmacogenetics; Pyridines; Ritonavir; Tenofovir; Young Adult | 2012 |
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; C-Reactive Protein; Coronary Disease; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Inflammation; Interleukin-6; Lamivudine; Lipids; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Ritonavir; Treatment Outcome; Young Adult | 2013 |
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Genetic Variation; Genotype; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Jaundice; Oligopeptides; Pyridines; Ritonavir | 2013 |
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation, Missense; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2012 |
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepacivirus; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2013 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load | 2012 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Surveys and Questionnaires; Tenofovir; Viral Load | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Bilirubin; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Young Adult; Zinc Sulfate | 2013 |
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Ritonavir | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Plasma; Pyridines; Ribavirin; Ritonavir | 2014 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Female; Genome-Wide Association Study; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Pyridines; Ritonavir | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Proteins; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neopterin; Oligopeptides; Protein Binding; Pyridines; Ritonavir; RNA, Viral; Sulfonamides | 2014 |
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).
Topics: Atazanavir Sulfate; CD4-CD8 Ratio; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Killer Cells, Natural; Oligopeptides; Pyridines; Ritonavir; RNA, Viral | 2014 |
Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pregnancy; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2014 |
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load | 2014 |
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Plasma; Pyridines; Ritonavir; Sex Characteristics; Time Factors; Treatment Failure; Treatment Outcome | 2014 |
Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.
Topics: Adolescent; Adult; Atazanavir Sulfate; Contraceptives, Oral, Synthetic; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; HIV Protease Inhibitors; HIV Seropositivity; Humans; Metabolic Clearance Rate; Norethindrone; Oligopeptides; Progestins; Pyridines; Radioimmunoassay; Ritonavir; Up-Regulation; Young Adult | 2015 |
[Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2014 |
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir | 2015 |
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphates; Piperazines; Ritonavir; Triazoles; Young Adult | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Male; Prospective Studies; Ritonavir | 2015 |
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Bone Density; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Kidney; Lamivudine; Lipids; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.
Topics: Adult; Atazanavir Sulfate; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult | 2016 |
Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Anti-Infective Agents; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Encephalitis; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Reverse Transcriptase Inhibitors; Ritonavir; Toxoplasmosis, Cerebral; Young Adult | 2016 |
Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Topics: Adolescent; Adult; Atazanavir Sulfate; Cohort Studies; Drug Administration Schedule; Europe; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Middle Aged; Ritonavir; Treatment Outcome; Young Adult | 2016 |
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Ritonavir; Viral Load; Young Adult | 2016 |
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bone Density; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomiz
Topics: Adult; Africa; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cognition; Cognition Disorders; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Middle Aged; Neuropsychological Tests; Nevirapine; Ritonavir; Young Adult | 2016 |
Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Topics: Adult; Atazanavir Sulfate; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, LDL; Male; Middle Aged; Quinolines; Ritonavir; Treatment Outcome; Triglycerides | 2016 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.
Topics: Adult; Atazanavir Sulfate; Biomarkers; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Real-Time Polymerase Chain Reaction; Ritonavir; Spinal Puncture; Viral Load | 2016 |
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Topics: Adolescent; Adult; Atazanavir Sulfate; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Pregnancy; Ritonavir; Thailand; Viral Load; Young Adult | 2016 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Female; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ritonavir; Valine; Young Adult | 2017 |
Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.
Topics: Absorption, Physiological; Achlorhydria; Administration, Oral; Adult; Atazanavir Sulfate; Betaine; Cross-Over Studies; Drug Interactions; Female; Food-Drug Interactions; HIV Protease Inhibitors; Humans; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Ritonavir; Young Adult | 2017 |
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Viral Load; Young Adult | 2017 |
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2017 |
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase
Topics: Adult; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Young Adult | 2017 |
Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment.
Topics: Adolescent; Adolescent Behavior; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Ritonavir; Self Report; Treatment Failure; Viral Load; Zimbabwe | 2017 |
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Organophosphates; Piperazines; Prodrugs; Ritonavir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2018 |
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Infant; Male; Powders; Ritonavir; RNA, Viral | 2018 |
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Ritonavir; Viral Load | 2018 |
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2018 |
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Inflammation; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2018 |
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Ritonavir | 2018 |
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Contraceptive Agents, Female; Contraceptive Agents, Hormonal; Contraceptive Devices, Female; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel; Drug Interactions; Ethinyl Estradiol; Female; Genetic Association Studies; Genotype; HIV Infections; Humans; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ritonavir; Vagina | 2020 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents.
Topics: Adolescent; Atazanavir Sulfate; Black People; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Male; Models, Biological; Ritonavir; Zimbabwe | 2020 |
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Clinical Trials, Phase II as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nigeria; Nitro Compounds; Pilot Projects; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Standard of Care; Thiazoles; Treatment Outcome; Viral Load; Young Adult | 2021 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Female; Hair; HIV Infections; Humans; Male; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load; Zimbabwe | 2021 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome | 2021 |
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Topics: Adenosine Monophosphate; Adult; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Healthy Volunteers; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Tenofovir; Uganda | 2021 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Topics: Acetylcysteine; Antiviral Agents; Atazanavir Sulfate; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Inflammation; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2023 |
289 other study(ies) available for atazanavir sulfate and ritonavir
| Article | Year |
|---|---|
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2003 |
[New treatment options for HIV-infected patients].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2004 |
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Gels; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Saquinavir | 2004 |
[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
Topics: Atazanavir Sulfate; Blood Glucose; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2004 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
FDA notifications. BMS issues letter about omeprazole.
Topics: Area Under Curve; Atazanavir Sulfate; Drug Industry; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Oligopeptides; Omeprazole; Pyridines; Randomized Controlled Trials as Topic; Ritonavir; United States; United States Food and Drug Administration | 2005 |
Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.
Topics: Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Oligopeptides; Prospective Studies; Proton Pump Inhibitors; Pyridines; Ritonavir | 2005 |
Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2005 |
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Carbamates; Deoxyglucose; Dose-Response Relationship, Drug; Furans; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Infusions, Intravenous; Insulin Resistance; Lopinavir; Male; Models, Animal; Muscle, Skeletal; Myocardium; Oligopeptides; Pyridines; Pyrimidinones; Rats; Ritonavir; Sulfonamides | 2005 |
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Oligopeptides; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.
Topics: Atazanavir Sulfate; Buprenorphine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Narcotics; Oligopeptides; Pyridines; Ritonavir | 2006 |
Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
Topics: Antacids; Atazanavir Sulfate; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Oligopeptides; Proton Pump Inhibitors; Pyridines; Ritonavir | 2006 |
Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzimidazoles; Contraindications; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Rabeprazole; Ritonavir | 2006 |
Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.
Topics: Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Ritonavir | 2006 |
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Hypertension; Indinavir; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nelfinavir; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir | 2006 |
Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir | 2006 |
External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.
Topics: Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Oligopeptides; Pyridines; Ritonavir; Species Specificity | 2006 |
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Combinations; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Failure; Treatment Outcome; Viral Load | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Statistics, Nonparametric | 2006 |
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Algorithms; Area Under Curve; Atazanavir Sulfate; Bayes Theorem; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Statistical; Oligopeptides; Population; Pyridines; Reproducibility of Results; Ritonavir; Treatment Outcome | 2006 |
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Tenofovir; Virus Replication | 2006 |
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lymphocytes; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2006 |
Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Patient Selection; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
Topics: Adipose Tissue; Animals; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Hypertriglyceridemia; Lopinavir; Male; Mice; Mice, Inbred C57BL; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Messenger; Time Factors; Triglycerides | 2006 |
Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Ritonavir | 2006 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir | 2006 |
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Genes, MDR; Genotype; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Logistic Models; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk; Ritonavir | 2007 |
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors | 2007 |
Meeting report. Report from ICAAC.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load | 2006 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
Topics: Adult; Atazanavir Sulfate; Cross-Over Studies; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Sex Factors | 2007 |
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
Topics: Adult; Aged; Area Under Curve; Atazanavir Sulfate; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Safety; Saquinavir | 2007 |
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
Topics: Atazanavir Sulfate; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Time Factors | 2007 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index | 2007 |
Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Area Under Curve; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Prospective Studies; Pyridines; Rifampin; Ritonavir; Tuberculosis | 2007 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States | 2007 |
The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.
Topics: Adult; Atazanavir Sulfate; C-Reactive Protein; CD4 Lymphocyte Count; CD8 Antigens; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Semen; Treatment Outcome; Viral Load | 2007 |
Alopecia associated with ritonavir-boosted atazanavir therapy.
Topics: Adult; Alopecia; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2007 |
Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent.
Topics: Adolescent; Adrenal Insufficiency; Albuterol; Androstadienes; Anti-HIV Agents; Anti-Inflammatory Agents; Atazanavir Sulfate; Cushing Syndrome; Drug Interactions; Drug Therapy, Combination; Female; Fluticasone; HIV Infections; Humans; Hydrocortisone; Oligopeptides; Pyridines; Ritonavir; Salmeterol Xinafoate | 2007 |
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
Topics: Adult; Analgesics, Opioid; Atazanavir Sulfate; Buprenorphine; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Substance-Related Disorders | 2007 |
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
Topics: Atazanavir Sulfate; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2007 |
Efavirenz urolithiasis.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Urolithiasis | 2007 |
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2007 |
Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir | 2007 |
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom | 2007 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2008 |
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2007 |
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
Topics: Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2008 |
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
Topics: Adult; Age Factors; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines; Ritonavir; Transaminases | 2008 |
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Mass Index; Body Weight; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS.
Topics: Androstadienes; Anti-Inflammatory Agents; Atazanavir Sulfate; Cushing Syndrome; Drug Interactions; Fluticasone; HIV Infections; HIV Protease Inhibitors; Humans; Iatrogenic Disease; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sarcoma, Kaposi | 2008 |
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Urolithiasis; Viral Load | 2008 |
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pilot Projects; Prospective Studies; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
Topics: Atazanavir Sulfate; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Outpatients; Plasma; Pyridines; Ritonavir; Sex; Tandem Mass Spectrometry | 2008 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2008 |
Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
Topics: Animals; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Blotting, Western; Chemistry, Pharmaceutical; Cyclosporine; Cytochrome P-450 CYP3A; Dosage Forms; Half-Life; Immunosuppressive Agents; Male; Oligopeptides; Pyridines; Rats; Rats, Wistar; Ritonavir; Spectrophotometry, Ultraviolet | 2008 |
The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Atazanavir Sulfate; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glucuronosyltransferase; Humans; Lamotrigine; Male; Middle Aged; Molecular Probe Techniques; Oligopeptides; Phenotype; Prospective Studies; Pyridines; Reference Values; Ritonavir; Sensitivity and Specificity; Triazines; Young Adult | 2008 |
Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.
Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Electrocardiography; HIV Infections; HIV Protease Inhibitors; Humans; Male; Methadone; Middle Aged; Narcotics; Oligopeptides; Pyridines; Ritonavir; Tachycardia, Ventricular | 2008 |
Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
Topics: Adult; Anticonvulsants; Atazanavir Sulfate; Cognition Disorders; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Minocycline; Oligopeptides; Pyridines; Ritonavir; Valproic Acid | 2008 |
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.
Topics: Adipocytes; Adipokines; Adult; Aged; Atazanavir Sulfate; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Omentum; Pyridines; Ritonavir; Subcutaneous Fat | 2008 |
Maraviroc: in vitro assessment of drug-drug interaction potential.
Topics: Area Under Curve; Atazanavir Sulfate; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Liver; Male; Maraviroc; Microsomes, Liver; Oligopeptides; Predictive Value of Tests; Pyridines; Ritonavir; Saquinavir; Triazoles | 2008 |
Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medical Audit; Multivariate Analysis; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2008 |
Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
Topics: Atazanavir Sulfate; Cat's Claw; Female; Herb-Drug Interactions; HIV Protease Inhibitors; Humans; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Plant Preparations; Pyridines; Ritonavir; Saquinavir | 2008 |
Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Thailand; Treatment Outcome | 2008 |
Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Cell Line; Cyclosporins; Diphosphonates; Endothelium, Vascular; HIV Protease Inhibitors; Humans; Microvessels; Oligopeptides; Propionates; Pyridines; Quinolines; Rifampin; Ritonavir; Tritium; Up-Regulation | 2009 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
Topics: Adult; Asian People; Atazanavir Sulfate; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Thailand | 2009 |
Protease inhibitor levels in hair strongly predict virologic response to treatment.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Monitoring; Epidemiologic Methods; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Pyrimidinones; Ritonavir; Specimen Handling; Treatment Outcome; Viral Load | 2009 |
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Topics: Amino Acid Sequence; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Chi-Square Distribution; Codon; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Synergism; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Longitudinal Studies; Male; Multivariate Analysis; Mutation; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2009 |
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States | 2009 |
96-week data from CASTLE study presented.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Female; Healthy Volunteers; HIV Infections; Humans; Middle Aged; Models, Statistical; Oligopeptides; Plasma; Pyridines; Ritonavir; Young Adult | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Hyperbilirubinemia; Liver; Male; Multivariate Analysis; Oligopeptides; Prevalence; Proportional Hazards Models; Pyridines; Risk Factors; Ritonavir; Severity of Illness Index | 2009 |
Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.
Topics: Adult; Age Factors; Aged; Atazanavir Sulfate; Cytochrome P-450 CYP3A Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pregnancy; Pyridines; Ritonavir; Saquinavir; Sex Factors; Young Adult | 2009 |
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Jaundice; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Torsades de Pointes; Viral Load | 2009 |
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Female; Gene Expression; Haplotypes; Humans; Male; Molecular Sequence Data; Oligopeptides; Plasma; Polymorphism, Genetic; Pyridines; Ritonavir; Sequence Analysis, DNA; Young Adult | 2009 |
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Topics: Adult; Atazanavir Sulfate; DNA Mutational Analysis; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Young Adult | 2009 |
Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.
Topics: Adult; Antipsychotic Agents; Atazanavir Sulfate; Dibenzothiazepines; Drug Interactions; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Quetiapine Fumarate; Ritonavir | 2009 |
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Bilirubin; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2010 |
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.
Topics: Adult; Atazanavir Sulfate; Chromatography, Liquid; Drug Monitoring; Female; HIV-1; Humans; Male; Methadone; Oligopeptides; Pharmaceutical Solutions; Plasma; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Solutions; Virus Diseases | 2010 |
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2010 |
[Viral resistance and genetic barrier of atazanavir].
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Genes, pol; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Models, Molecular; Multicenter Studies as Topic; Mutation; Mutation, Missense; Oligopeptides; Point Mutation; Protein Conformation; Pyridines; Ritonavir; Structure-Activity Relationship | 2008 |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.
Topics: Animals; Atazanavir Sulfate; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Darunavir; Dose-Response Relationship, Drug; Fatty Acid Transport Proteins; Fatty Acids; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligopeptides; Oxidation-Reduction; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides | 2010 |
Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.
Topics: Adipocytes; Adiponectin; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cell Differentiation; Cell Proliferation; Cells, Cultured; Fatty Acid-Binding Proteins; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Oligopeptides; PPAR gamma; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir | 2010 |
Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.
Topics: Animals; Antigens, Surface; Atazanavir Sulfate; Berberine; Blotting, Western; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; ELAV Proteins; ELAV-Like Protein 1; Endoplasmic Reticulum; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; HIV Protease Inhibitors; Inflammation Mediators; Interleukin-6; Lopinavir; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA-Binding Proteins; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |
Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Hepatocytes; Humans; Oligopeptides; Pregnane X Receptor; Pyridines; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Transfection | 2010 |
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Topics: Animals; Atazanavir Sulfate; Carbamates; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; HIV Protease Inhibitors; Hyperlipidemias; Male; Oligonucleotide Array Sequence Analysis; Oligopeptides; Proteasome Endopeptidase Complex; Pyridines; Rats; Rats, Sprague-Dawley; Ritonavir; Sulfonamides | 2010 |
Single-tablet Quad regimen achieves high rate of virologic suppression.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cells, Cultured; Cyclopropanes; Delayed-Action Preparations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunohistochemistry; Macrophages; Microscopy, Confocal; Microscopy, Electron, Transmission; Nanoconjugates; Nanotechnology; Oligopeptides; Pyridines; Ritonavir | 2010 |
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Topics: Adolescent; Adult; Aged; Alkynes; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proguanil; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Fasting; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Patient Satisfaction; Prospective Studies; Pyridines; Ritonavir; Transaminases; Treatment Outcome; Triglycerides; Viral Load | 2010 |
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Blood Proteins; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.
Topics: Algorithms; Animals; Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; Biological Transport, Active; Blotting, Western; Caco-2 Cells; Cell Line; Dogs; Drug Interactions; Estrone; Humans; Hydrogen-Ion Concentration; Oligopeptides; Organic Anion Transporters; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir | 2010 |
HIV protease inhibitors activate the adipocyte renin angiotensin system.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atazanavir Sulfate; Benzimidazoles; Benzoates; Biphenyl Compounds; HIV Protease Inhibitors; Humans; Irbesartan; Lopinavir; Mice; Oligopeptides; PPAR gamma; Pyridines; Pyrimidinones; Renin-Angiotensin System; Ritonavir; Telmisartan; Tetrazoles | 2010 |
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
Topics: Atazanavir Sulfate; ATP-Binding Cassette Transporters; Cell Line; Drug Resistance, Multiple; Enzyme Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2010 |
Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.
Topics: Adult; Atazanavir Sulfate; Carrier Proteins; Female; Gene Expression; HIV Protease Inhibitors; Humans; Inflammation; Interleukin-6; Intra-Abdominal Fat; Lopinavir; Male; Nelfinavir; Oligopeptides; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Pyridines; Pyrimidinones; Ritonavir; Sesquiterpenes; Subcutaneous Fat; Triglycerides; Tumor Necrosis Factor-alpha | 2011 |
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Topics: Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; HIV-1; Humans; Indinavir; Macrophages; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Oligopeptides; Particle Size; Pyridines; Ritonavir; Static Electricity; Surface-Active Agents; Virus Replication | 2011 |
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Body Fat Distribution; Body Mass Index; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Young Adult | 2011 |
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cost-Benefit Analysis; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Sweden | 2011 |
GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Biological Transport; Cells, Cultured; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Homeostasis; Humans; Insulin; Lopinavir; Male; Mice; Molecular Structure; Oligopeptides; Pyridines; Pyrimidinones; Rats; Rats, Wistar; Ritonavir | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.
Topics: Africa, Northern; Atazanavir Sulfate; Crystallization; Drug Therapy, Combination; France; Granulomatous Disease, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nephritis, Interstitial; Oligopeptides; Pyridines; Ritonavir | 2011 |
Medication-based urolithiasis and atazanavir.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Uric Acid; Urinary Calculi; Urolithiasis | 2011 |
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Middle Aged; Norgestrel; Oligopeptides; Pyridines; Ritonavir; Women's Health; Young Adult | 2011 |
Interaction between antiretroviral drugs and acenocoumarol.
Topics: Acenocoumarol; Alkynes; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Venous Thrombosis | 2011 |
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cohort Studies; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Jaundice, Neonatal; Male; Maternal-Fetal Exchange; Medical Records; Oligopeptides; Phototherapy; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Pyridines; Retrospective Studies; Ritonavir | 2011 |
Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Monitoring; Female; Fibrosis; Hepacivirus; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2011 |
Cushing's syndrome due to antiretroviral-budesonide interaction.
Topics: Aged; Atazanavir Sulfate; Budesonide; Cushing Syndrome; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Glucocorticoids; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2011 |
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; Humans; Male; Models, Biological; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tissue Distribution | 2011 |
Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Monitoring, Physiologic; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Statistics as Topic; Treatment Outcome | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Topics: Alkynes; Animal Structures; Animals; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; Humans; Indinavir; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Pyridines; Ritonavir; Tandem Mass Spectrometry | 2011 |
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atazanavir Sulfate; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Lopinavir; Macrophages; Mice; Mice, SCID; Mice, Transgenic; Nelfinavir; Neurons; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2012 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.
Topics: Adenine; Adrenal Insufficiency; Adult; Atazanavir Sulfate; Cushing Syndrome; Cytochrome P-450 Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Iatrogenic Disease; Injections, Intramuscular; Lamivudine; Oligopeptides; Organophosphonates; Pruritus; Pyridines; Ritonavir; Tenofovir; Triamcinolone Acetonide | 2011 |
HIV protease inhibitors induce metabolic dysfunction in part via increased JNK1/2 pro-inflammatory signaling in L6 cells.
Topics: Animals; Atazanavir Sulfate; Cell Line; Glucose; HIV Protease Inhibitors; Insulin Resistance; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Muscle Fibers, Skeletal; Oligopeptides; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Palmitates; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Rats; Ritonavir; Signal Transduction; Time Factors | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; Carbamates; Carboxylic Ester Hydrolases; Drug Interactions; Furans; Humans; Kinetics; Models, Molecular; Nelfinavir; Oligopeptides; Protease Inhibitors; Pyridines; Quantitative Structure-Activity Relationship; Ritonavir; Saquinavir; Sulfonamides | 2012 |
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cell Survival; Chemistry, Pharmaceutical; Cyclopropanes; Histocytochemistry; Humans; Indinavir; Macrophages; Nanomedicine; Nanoparticles; Nanotechnology; Oligopeptides; Pyridines; Ritonavir; Sonication | 2011 |
Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Cell Differentiation; Cells, Cultured; Darunavir; HIV Protease Inhibitors; Humans; Insulin Resistance; Lipolysis; Lopinavir; Mice; Mitochondria; Oligopeptides; Pyridines; Reactive Oxygen Species; Ritonavir; Sulfonamides | 2012 |
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Oligopeptides; Organophosphonates; Prednisone; Pyridines; Ritonavir; Sarcoidosis; Tenofovir; Young Adult | 2012 |
A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
Topics: Acquired Immunodeficiency Syndrome; Adult; Atazanavir Sulfate; Black or African American; Cost-Benefit Analysis; Cytochrome P-450 CYP3A; Female; Genotype; Haplotypes; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyridines; Ritonavir; Treatment Outcome; White People; Young Adult | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Coinfection; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; HIV Infections; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Oligopeptides; Organophosphonates; Prednisone; Pseudolymphoma; Pyridines; Ritonavir; Skin; Tenofovir | 2012 |
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Costs and Cost Analysis; Drug Therapy, Combination; Health Status; HIV Protease Inhibitors; Humans; Lopinavir; Markov Chains; Oligopeptides; Pyridines; Quality of Life; Ritonavir; United Kingdom; Viral Load | 2012 |
Effect of HIV protease inhibitors on New World Leishmania.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; HIV Protease Inhibitors; Indinavir; Leishmania; Leishmaniasis, Cutaneous; Mice; Oligopeptides; Pyridines; Ritonavir | 2012 |
Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.
Topics: AIDS Vaccines; Atazanavir Sulfate; Cell Line; HIV Antigens; HIV Protease Inhibitors; Humans; Lopinavir; Microbial Sensitivity Tests; Oligopeptides; Pyridines; Ritonavir; Vaccinia virus; Virus Replication | 2012 |
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Topics: Adult; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Blood-Brain Barrier; Brain; Cells, Cultured; Coculture Techniques; Drug Carriers; Drug Delivery Systems; Endothelial Cells; Folic Acid; HIV Infections; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Mononuclear Phagocyte System; Nanoparticles; Oligopeptides; Pyridines; Ritonavir; Spleen; Tissue Distribution; Viral Load | 2012 |
High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Kidney Calculi; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2012 |
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Topics: Animals; Anti-HIV Agents; Antigens, CD34; Atazanavir Sulfate; Brain; Dosage Forms; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; HIV-1; Immunohistochemistry; Mice; Mice, Inbred NOD; Nanoparticles; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Child; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Oligopeptides; Organophosphates; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV-2; Humans; Mutation; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2013 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Male; Middle Aged; Models, Statistical; Oligopeptides; Plasma; Pyridines; Ritonavir; Young Adult | 2013 |
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Data Collection; Databases, Factual; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Female; Humans; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir | 2013 |
Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Ritonavir; Salivary Gland Calculi | 2013 |
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Computer Simulation; Drug Monitoring; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Nomograms; Oligopeptides; Pyridines; Reproducibility of Results; Ritonavir | 2013 |
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
Topics: Adult; Aged; Atazanavir Sulfate; Australia; Comorbidity; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Ritonavir; Stroke; Time Factors; Treatment Outcome; United States; Viral Load | 2013 |
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
Topics: Adiposity; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Bone and Bones; Cognition; Drug Resistance, Viral; Endpoint Determination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Oligopeptides; Patient Compliance; Pilot Projects; Pregnancy; Pyridines; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure | 2013 |
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2013 |
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; HIV Infections; Humans; Italy; Lopinavir; Oligopeptides; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Ritonavir | 2013 |
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Topics: Alkynes; Anti-Retroviral Agents; Antidepressive Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Humans; Models, Biological; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2013 |
Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir.
Topics: Adenine; Adult; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Female; Genotype; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cell Movement; Cells, Cultured; Chemokines; Cyclopropanes; Cytoskeletal Proteins; Drug Carriers; Drug Compounding; Humans; Macrophages; Membrane Potentials; Nanoparticles; Oligopeptides; Particle Size; Phagocytosis; Potassium Channels; Proteome; Pyridines; Ritonavir | 2013 |
Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Sex Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Macaca mulatta; Macrophages; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Pyridines; Ritonavir; Tissue Distribution | 2013 |
Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbazoles; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Half-Life; HIV Infections; HIV-1; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Nootropic Agents; Oligopeptides; Protein Kinase Inhibitors; Pyridines; Ritonavir | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
Topics: Adult; Atazanavir Sulfate; Cholelithiasis; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2013 |
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2013 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir | 2013 |
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Proportional Hazards Models; Pyridines; Retrospective Studies; Ritonavir; Sulfonamides | 2013 |
Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
Topics: Adult; Antibiotics, Antitubercular; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; India; Male; Microbial Sensitivity Tests; Oligopeptides; Polypharmacy; Pyridines; Rifabutin; Ritonavir; Tuberculosis | 2013 |
Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Resistance, Viral; Female; Genes, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Mutation; Oligopeptides; Pyridines; Retrospective Studies; Risk Factors; Ritonavir; Viral Load | 2014 |
Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
Topics: Animals; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Brain Chemistry; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; HIV Protease Inhibitors; Male; Mice; Mice, Knockout; Oligopeptides; Pyridines; Ritonavir; Seminiferous Tubules; Testis | 2014 |
Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection.
Topics: Abdomen; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cholelithiasis; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Prevalence; Pyridines; Ritonavir; Time Factors; Ultrasonography | 2014 |
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cross-Sectional Studies; Glucuronosyltransferase; Greece; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Genetic; Prevalence; Pyridines; Ritonavir | 2014 |
Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cellular Senescence; Darunavir; Drug Synergism; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Nitric Oxide; Oligopeptides; Oxidative Stress; Pravastatin; Pyridines; Ritonavir; Sulfonamides | 2014 |
Metronidazole or Cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs.
Topics: Administration, Oral; Analysis of Variance; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Biological Availability; Colon; Electric Conductivity; HIV Infections; Intestinal Absorption; Male; Metronidazole; Oligopeptides; Pyridines; Rats; Rats, Sprague-Dawley; Ritonavir; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.
Topics: Atazanavir Sulfate; Darunavir; HIV Protease Inhibitors; Humans; Oligopeptides; Plasma; Pyridines; Ritonavir; Sulfonamides | 2014 |
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; C-Reactive Protein; CD4 Lymphocyte Count; Chemokine CXCL10; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Immune System; Inflammation; Interferon-gamma; Interleukin-6; Lipopolysaccharide Receptors; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cell Extracts; Chromatography, Liquid; Cyclopropanes; Darunavir; Humans; Leukocytes, Mononuclear; Lopinavir; Mass Spectrometry; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2014 |
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Ritonavir; Young Adult | 2014 |
Managing drug-drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: a 'tour de force' for clinical pharmacologists.
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Carbamazepine; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Drug Interactions; Drug Monitoring; Enzyme Activation; Epilepsy; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
Topics: Adult; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Biomarkers; Female; Humans; Intracellular Fluid; Leukocytes, Mononuclear; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Oligopeptides; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pregnane X Receptor; Pyridines; Receptors, Steroid; Ritonavir | 2014 |
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
Topics: Adult; Aged; Atazanavir Sulfate; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pulmonary Aspergillosis; Pyridines; Ritonavir; Voriconazole | 2014 |
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2014 |
Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
Topics: Adult; Age Factors; Atazanavir Sulfate; Body Weight; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Ritonavir; Rosuvastatin Calcium; Sex Factors; Viral Load | 2015 |
Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Carriers; Drug Compounding; Drug Evaluation, Preclinical; Folic Acid; Food, Formulated; Half-Life; Humans; Injections, Intramuscular; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Nanostructures; Oligopeptides; Poloxamer; Pyridines; Ritonavir; Tissue Distribution | 2014 |
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Bone Density; HIV Infections; HIV-1; Humans; Lopinavir; Multivariate Analysis; Oligopeptides; Pyridines; Ritonavir | 2015 |
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Topics: Animals; Anti-Retroviral Agents; Antigens, CD; Atazanavir Sulfate; Chemistry, Pharmaceutical; Flow Cytometry; Folate Receptor 1; HIV Core Protein p24; Humans; Liver; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Nanoparticles; Oligopeptides; Poloxamer; Pyridines; Ritonavir; Spleen; T-Lymphocytes; Tissue Distribution | 2015 |
Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cytokines; Female; Hydrogen Peroxide; Immunity, Innate; Leishmania; Leishmaniasis; Lopinavir; Macrophages, Peritoneal; Mice, Inbred BALB C; NF-kappa B; Nitrites; PPAR gamma; Ritonavir | 2015 |
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-Retroviral Agents; Asia; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Survival Analysis; Treatment Failure; Viral Load; Young Adult | 2015 |
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Administration Schedule; Drug Combinations; Female; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Viral Load | 2015 |
Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir | 2015 |
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir | 2015 |
[Cutaneous CD8+ T-cell lymphoma. Regression after HIV antiviral triple therapy].
Topics: Alopecia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Clone Cells; Dideoxynucleosides; Drug Therapy, Combination; Humans; Immunophenotyping; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Ritonavir | 2015 |
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Nephrolithiasis; Ritonavir; Viral Load | 2015 |
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Hospitals, Teaching; Humans; Lopinavir; Male; Middle Aged; Nigeria; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Topics: Animals; Anti-Retroviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Delayed-Action Preparations; Drug Carriers; Folate Receptors, GPI-Anchored; Folic Acid; HIV Infections; Humans; Injections, Intramuscular; Mice, SCID; Nanomedicine; Nanoparticles; Poloxamer; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Lopinavir; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir | 2015 |
Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Topics: Adolescent; Adult; Atazanavir Sulfate; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Lopinavir; Middle Aged; Pregnancy; Pregnancy Outcome; Premature Birth; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2016 |
A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2015 |
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Coinfection; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Models, Biological; Nonlinear Dynamics; Renal Elimination; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand; Treatment Outcome | 2015 |
Choice of effect measure in HIV randomized trials.
Topics: Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Endpoint Determination; HIV Infections; HIV-1; Humans; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Time; Treatment Outcome; Viral Load | 2015 |
Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; Health Expenditures; Health Services; HIV Infections; Humans; Male; Medicaid; Medication Adherence; Middle Aged; Models, Econometric; Propensity Score; Retrospective Studies; Ritonavir; Socioeconomic Factors; United States | 2016 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult | 2016 |
Acute intermittent porphyria precipitated by atazanavir/ritonavir.
Topics: Abdominal Pain; Atazanavir Sulfate; Female; HIV Infections; Humans; Middle Aged; Porphyria, Acute Intermittent; Protease Inhibitors; Ritonavir; Treatment Outcome | 2016 |
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2016 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction.
Topics: Acetylcysteine; Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Ritonavir; Rotenone | 2016 |
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir | 2016 |
Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations.
Topics: Atazanavir Sulfate; Biological Transport; Caco-2 Cells; Cell Membrane; Dosage Forms; Drug Compounding; Drug Liberation; HIV Protease Inhibitors; Humans; Lopinavir; Ritonavir; Solubility | 2016 |
Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Benzazepines; Bradycardia; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Emtricitabine; Female; Heart Failure; HIV Infections; Humans; Ivabradine; Middle Aged; Ritonavir; Tenofovir | 2016 |
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lopinavir; Male; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Ritonavir | 2016 |
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Atazanavir Sulfate; Cytochrome P-450 CYP2C19; Drug Combinations; Drug Interactions; Female; Genotype; Healthy Volunteers; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Voriconazole; Young Adult | 2017 |
Atazanavir dose reduction: one size does not fit all.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; DNA, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocytes, Mononuclear; Pilot Projects; Polymerase Chain Reaction; Ritonavir | 2016 |
Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibiotics, Antitubercular; Atazanavir Sulfate; Child; Child, Preschool; Coinfection; Dose-Response Relationship, Drug; Electronic Health Records; Female; HIV Infections; Humans; India; Infant; Male; Middle Aged; Retrospective Studies; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis; Young Adult | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
Topics: Adult; Age Factors; Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Sex Factors; Viral Load | 2016 |
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Coinfection; Drug Resistance, Viral; Drug Substitution; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retreatment; Retrospective Studies; Ritonavir; Time-to-Treatment; Treatment Outcome; Viral Load | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
Topics: Animals; Atazanavir Sulfate; Bilirubin; Cells, Cultured; Female; Glucuronosyltransferase; Glutathione Transferase; Hepatocytes; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Rats, Wistar; Ritonavir; Substance-Related Disorders | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; British Columbia; Canada; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2017 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Malawi; Male; Medication Adherence; Middle Aged; Ritonavir; Treatment Failure; Urban Health; Viral Load | 2017 |
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Leukocytes, Mononuclear; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prospective Studies; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Viral Load | 2018 |
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Topics: Adolescent; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Longitudinal Studies; Male; Ritonavir; Viral Load; Young Adult | 2018 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Simultaneous Determination of Impurities of Atazanavir and Ritonavir in Tablet Dosage Form by Using Reversed-Phase Ultra Performance Liquid Chromatographic Method.
Topics: Atazanavir Sulfate; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Contamination; Limit of Detection; Linear Models; Reproducibility of Results; Ritonavir; Tablets | 2018 |
PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Synergism; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Liver-Specific Organic Anion Transporter 1; Pharmacogenetics; Pregnane X Receptor; Ritonavir | 2018 |
Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atazanavir Sulfate; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; India; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Young Adult | 2018 |
HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis.
Topics: Animals; Atazanavir Sulfate; Cytokines; Female; HIV Protease Inhibitors; Leishmaniasis; Leukocyte Count; Leukocytes; Lopinavir; Mice, Inbred BALB C; Nitric Oxide; Ritonavir; Skin; Spleen | 2018 |
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.
Topics: Adult; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver-Specific Organic Anion Transporter 1; Polymorphism, Single Nucleotide; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Pregnane X Receptor; Prospective Studies; Ritonavir | 2018 |
Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats.
Topics: Animals; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Dogs; Drug Interactions; Female; HIV Protease Inhibitors; Madin Darby Canine Kidney Cells; Maternal-Fetal Exchange; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Placenta; Pregnancy; Rats, Wistar; Ritonavir | 2018 |
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Endothelial Cells; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Lymphocyte Activation; Male; Prospective Studies; Pulse Wave Analysis; Random Allocation; Ritonavir | 2018 |
Crystallization from Supersaturated Solutions: Role of Lecithin and Composite Simulated Intestinal Fluid.
Topics: Algorithms; Atazanavir Sulfate; Calcium Channel Blockers; Crystallization; Dihydropyridines; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Intestinal Secretions; Lecithins; Pharmaceutical Preparations; Ritonavir; Solubility; Solutions; Tacrolimus | 2018 |
Chronic granulomatous interstitial nephritis and urothelial metaplasia associated with ritonavir-boosted atazanavir: a case study and literature review.
Topics: Atazanavir Sulfate; HIV Infections; Humans; Male; Metaplasia; Middle Aged; Nephritis, Interstitial; Ritonavir; Urothelium | 2018 |
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; HIV Infections; Humans; Leukocytes, Mononuclear; Lipids; Lymphocytes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Monitoring; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Tablets; Time Factors; Treatment Outcome | 2018 |
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inflammation; Male; Middle Aged; Prospective Studies; Ritonavir | 2018 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.
Topics: Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Dietary Supplements; Disease Models, Animal; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lipogenesis; Liver; Magnesium; Male; NF-E2-Related Factor 2; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Inbred F344; Rats, Transgenic; Ritonavir | 2019 |
Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes.
Topics: Acetyltransferases; Anti-HIV Agents; Astrocytes; Atazanavir Sulfate; Chromosomal Proteins, Non-Histone; Dideoxynucleosides; Drug Combinations; Emtricitabine; Gene Expression Regulation; Histone Deacetylases; HIV-1; Host-Pathogen Interactions; Humans; Lopinavir; Lysosomes; Membrane Proteins; Mitochondria; Morphine; Narcotics; Nuclear Proteins; Primary Cell Culture; Protein-Arginine N-Methyltransferases; Raltegravir Potassium; Ritonavir; Sequestosome-1 Protein; Signal Transduction; Trans-Activators; Virus Replication | 2019 |
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Ritonavir; Uganda; Viral Load | 2019 |
Influence of
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Polymorphism, Genetic; Ritonavir; Thailand | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Caco-2 Cells; Carbamates; Drug Interactions; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Imidazoles; Intestines; Lopinavir; Male; Maraviroc; Middle Aged; Pyrrolidines; Rats; Rats, Wistar; Ritonavir; Saquinavir; Valine; Zidovudine | 2019 |
Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Contraceptive Agents; Contraceptive Devices, Female; Cyclopropanes; Desogestrel; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Lynestrenol; Middle Aged; Progesterone; Ritonavir; Viral Load; Young Adult | 2019 |
Cotrimoxazole Prophylaxis is Not Associated with a Higher Occurrence of Atazanavir Treatment Failure: Analysis of Worldwide Pharmacovigilance Data.
Topics: Africa; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Pharmacovigilance; Ritonavir; Treatment Failure; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Comorbidity; Coronary Vessels; Endothelial Cells; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Male; Maraviroc; NF-kappa B; Oxazines; Piperazines; Pyridones; Ritonavir; Signal Transduction; Sirtuin 1; Ubiquitin Thiolesterase | 2020 |
Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.
Topics: Atazanavir Sulfate; Blood-Brain Barrier; Curcumin; Drug Carriers; Drug Compounding; HIV Infections; HIV-1; Humans; Laser Therapy; Nanoparticles; Precision Medicine; Ritonavir; Theranostic Nanomedicine | 2020 |
COVID-19 & antiepileptic drugs: Should we pay attention?
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Carbamazepine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Lopinavir; Pandemics; Phenytoin; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Seizures | 2020 |
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Topics: Animals; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cell Death; Chlorocebus aethiops; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Cytokines; Drug Therapy, Combination; Humans; Inflammation; Lopinavir; Molecular Docking Simulation; Monocytes; Pandemics; Pneumonia, Viral; Protease Inhibitors; Ritonavir; SARS-CoV-2; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2020 |
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Intensive Care Units; Length of Stay; Male; Middle Aged; Prospective Studies; Ritonavir; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca
Topics: Alkynes; Animals; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Calcium; Cell Line; Cyclopropanes; Homeostasis; Mice; Muscle, Skeletal; Myoblasts; Rabbits; Ritonavir; Ryanodine; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Time-Lapse Imaging | 2021 |
Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
Topics: Adult; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Atazanavir Sulfate; Case-Control Studies; Chromatography, High Pressure Liquid; Drug Combinations; Female; HIV Infections; Hospitals, Teaching; Humans; Malaria; Male; Middle Aged; Nigeria; Plasmodium falciparum; Racemases and Epimerases; Ritonavir | 2021 |
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Emtricitabine; Humans; Lamivudine; Lopinavir; Molecular Docking Simulation; Nucleosides; Protease Inhibitors; Ritonavir; SARS-CoV-2 | 2021 |
Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Contraceptive Agents; Desogestrel; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2022 |
Impact of Simulated Intestinal Fluids on Dissolution, Solution Chemistry, and Membrane Transport of Amorphous Multidrug Formulations.
Topics: Administration, Oral; Atazanavir Sulfate; Body Fluids; Cell Membrane; Chemistry, Pharmaceutical; Drug Combinations; Felodipine; Indapamide; Intestines; Membranes, Artificial; Ritonavir; Solubility | 2021 |
Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Rifampin; Ritonavir | 2022 |
Potential interactions between antineoplastic agents and medicines used to treat Covid-19.
Topics: Antineoplastic Agents; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Lopinavir; Ritonavir | 2022 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization | 2021 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Ethiopia; Female; Glucose; Glucose Metabolism Disorders; HIV; HIV Infections; Humans; Insulin; Male; Prevalence; Ritonavir | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Durability of switched therapy after failure of WHO-recommended antiretroviral therapy regimens in a resource-limited setting.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Retrospective Studies; Ritonavir; Viral Load; World Health Organization; Young Adult | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal.
Topics: Aging, Premature; Animals; Anti-HIV Agents; Atazanavir Sulfate; Cellular Senescence; Darunavir; HIV Infections; HIV Protease Inhibitors; Mice; Ritonavir | 2023 |
Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily G, Member 2; Darunavir; Drug Interactions; Lopinavir; Neoplasm Proteins; Protease Inhibitors; Ritonavir; Rosuvastatin Calcium | 2023 |
Potential association between chia seeds use and low atazanavir trough concentrations in an HIV-infected patient.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Pyridines; Ritonavir | 2023 |
Evaluating variations in bilirubin glucuronidation activity by protease inhibitors in canine and human primary hepatocytes cultured in a 3D culture system.
Topics: Animals; Atazanavir Sulfate; Bilirubin; Dogs; Hepatocytes; Humans; Liver; Protease Inhibitors; Ritonavir; Spheroids, Cellular | 2023 |